Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO.

Tateno A, Sakayori T, Kim WC, Honjo K, Nakayama H, Arakawa R, Okubo Y.

Int J Neuropsychopharmacol. 2018 Jun 1;21(6):522-527. doi: 10.1093/ijnp/pyy004.

2.

Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925.

Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P, Bhathena A, Palaparthy R, Saltarelli MD, Kapur S.

Int J Neuropsychopharmacol. 2010 Apr;13(3):273-87. doi: 10.1017/S1461145709990642. Epub 2009 Sep 15.

PMID:
19751545
3.

The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.

Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, Rusjan P, Houle S, Wilson AA, Kapur S.

Arch Gen Psychiatry. 2009 Jun;66(6):606-15. doi: 10.1001/archgenpsychiatry.2009.43.

PMID:
19487625
4.

Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.

Baba S, Enomoto T, Horisawa T, Hashimoto T, Ono M.

J Pharmacol Sci. 2015 Mar;127(3):326-31. doi: 10.1016/j.jphs.2015.01.007. Epub 2015 Feb 7.

5.

Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.

Tateno A, Arakawa R, Okumura M, Fukuta H, Honjo K, Ishihara K, Nakamura H, Kumita S, Okubo Y.

J Clin Psychopharmacol. 2013 Apr;33(2):162-9. doi: 10.1097/JCP.0b013e3182825bce.

PMID:
23422369
6.

Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task.

Suridjan I, Rusjan P, Addington J, Wilson AA, Houle S, Mizrahi R.

J Psychiatry Neurosci. 2013 Mar;38(2):98-106. doi: 10.1503/jpn.110181.

7.

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.

Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. Epub 2016 Aug 15.

8.

Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.

Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, Zack M, Furukawa Y, McCluskey T, Wilson AA, Kish SJ.

J Neurosci. 2012 Jan 25;32(4):1353-9. doi: 10.1523/JNEUROSCI.4371-11.2012.

9.

Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).

Vernaleken I, Fellows C, Janouschek H, Bröcheler A, Veselinovic T, Landvogt C, Boy C, Buchholz HG, Spreckelmeyer K, Bartenstein P, Cumming P, Hiemke C, Rösch F, Schäfer W, Wong DF, Gründer G.

J Clin Psychopharmacol. 2008 Dec;28(6):608-17. doi: 10.1097/JCP.0b013e31818ba2f6.

PMID:
19011428
10.

Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.

Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E, Reeder S, Rabiner E, Laruelle M.

Synapse. 2006 Dec 1;60(7):485-95.

PMID:
16952157
11.

A Preliminary Investigation of the Effect of Acute Alcohol on Dopamine Transmission as Assessed by [11 C]-(+)-PHNO.

Thiruchselvam T, Wilson AA, Boileau I, Le Foll B.

Alcohol Clin Exp Res. 2017 Jun;41(6):1112-1119. doi: 10.1111/acer.13403. Epub 2017 May 29.

PMID:
28421623
12.

Lack of age-dependent decrease in dopamine D3 receptor availability: a [(11)C]-(+)-PHNO and [(11)C]-raclopride positron emission tomography study.

Nakajima S, Caravaggio F, Boileau I, Chung JK, Plitman E, Gerretsen P, Wilson AA, Houle S, Mamo DC, Graff-Guerrero A.

J Cereb Blood Flow Metab. 2015 Nov;35(11):1812-8. doi: 10.1038/jcbfm.2015.129. Epub 2015 Jun 10.

13.

Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.

Graff-Guerrero A, Willeit M, Ginovart N, Mamo D, Mizrahi R, Rusjan P, Vitcu I, Seeman P, Wilson AA, Kapur S.

Hum Brain Mapp. 2008 Apr;29(4):400-10.

PMID:
17497628
14.

Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.

Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, Wilson AA, Merlo-Pich E, Houle S, Gunn R, Rabiner EA, Laruelle M.

Biol Psychiatry. 2010 Aug 15;68(4):392-9. doi: 10.1016/j.biopsych.2010.04.038.

15.

Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.

Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS.

Psychopharmacology (Berl). 2000 Jun;150(2):132-40.

PMID:
10907666
16.

Estimating endogenous dopamine levels at D2 and D3 receptors in humans using the agonist radiotracer [(11)C]-(+)-PHNO.

Caravaggio F, Nakajima S, Borlido C, Remington G, Gerretsen P, Wilson A, Houle S, Menon M, Mamo D, Graff-Guerrero A.

Neuropsychopharmacology. 2014 Nov;39(12):2769-76. doi: 10.1038/npp.2014.125. Epub 2014 May 30.

17.

The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro.

McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, Wilson AA.

Neuropsychopharmacology. 2010 Jul;35(8):1826-35. doi: 10.1038/npp.2010.50. Epub 2010 Apr 21.

18.

Age-related changes in binding of the D2/3 receptor radioligand [(11)C](+)PHNO in healthy volunteers.

Matuskey D, Worhunksy P, Correa E, Pittman B, Gallezot JD, Nabulsi N, Ropchan J, Sreeram V, Gudepu R, Gaiser E, Cosgrove K, Ding YS, Potenza MN, Huang Y, Malison RT, Carson RE.

Neuroimage. 2016 Apr 15;130:241-247. doi: 10.1016/j.neuroimage.2016.02.002. Epub 2016 Feb 11.

19.

Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.

Abi-Jaoude E, Segura B, Obeso I, Cho SS, Houle S, Lang AE, Rusjan P, Sandor P, Strafella AP.

Hum Brain Mapp. 2015 Jul;36(7):2592-601. doi: 10.1002/hbm.22793. Epub 2015 Mar 18.

PMID:
25788222
20.

High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO.

Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P, Wilson AA.

Biol Psychiatry. 2006 Mar 1;59(5):389-94. Epub 2005 Dec 20.

PMID:
16373068

Supplemental Content

Support Center